Breaking News, Financial News

Financial Report: Amgen

Revenues up 10% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen   3Q Revenues: $4.7 billion (+10%) 3Q Earnings: $1.4 billion (+24%) YTD Revenues: $13.7 billion (+6%) YTD Earnings: $4.1 billion (+14%) Comments: Neulasta/Neupogen sales were up 18% to $1.3 billion in the quarter. Enbrel sales increased 7% to $1.1 billion. Epogen sales were flat at $491 million. Xgeva/ Prolia sales increased 41% to $303 million. Sensipar/Mimpara sales increased 7% to $183 million....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters